Kane Biotech Showcases revyve Wound Gel Data at WCET–NSWOCC Congress
Event summary
- Kane Biotech presented data on revyve Antimicrobial Wound Gel at the WCET–NSWOCC 2026 Joint Congress, held April 24–28 in Vancouver.
- The company showcased a case study on diabetic foot ulcer healing using revyve, emphasizing biofilm disruption.
- Engaged with clinicians from Canada and international markets, focusing on chronic wound challenges and antimicrobial solutions.
- Revyve products are FDA-cleared and Health Canada-approved, targeting biofilm-related antibiotic resistance in wounds.
The big picture
Kane Biotech’s participation in the WCET–NSWOCC Congress underscores the growing focus on biofilm-targeting therapies in chronic wound care. With antibiotic resistance driving demand for alternative solutions, the company’s FDA- and Health Canada-cleared revyve products position it in a niche market. The strategic emphasis on clinician education suggests a long-term play to shift treatment paradigms, though commercialization success will hinge on adoption rates and reimbursement dynamics.
What we're watching
- Clinical Adoption
- How quickly revyve integrates into standard wound care protocols following clinician engagement.
- Regulatory Expansion
- Whether Kane Biotech seeks additional approvals beyond the U.S. and Canada.
- Commercialization Pace
- The speed at which Kane Biotech scales distribution of revyve products globally.
Related topics